| Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial JA Cohen, AJ Coles, DL Arnold, C Confavreux, EJ Fox, HP Hartung, ... The Lancet 380 (9856), 1819-1828, 2012 | 1252 | 2012 |
| Alemtuzumab CARE-MS II 5-year follow-up: efficacy and safety findings AJ Coles, JA Cohen, EJ Fox, G Giovannoni, HP Hartung, E Havrdova, ... Neurology 89 (11), 1117-1126, 2017 | 275 | 2017 |
| Alemtuzumab CARE-MS I 5-year follow-up: durable efficacy in the absence of continuous MS therapy E Havrdova, DL Arnold, JA Cohen, HP Hartung, EJ Fox, G Giovannoni, ... Neurology 89 (11), 1107-1116, 2017 | 229 | 2017 |
| Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients G Giovannoni, JA Cohen, AJ Coles, HP Hartung, E Havrdova, KW Selmaj, ... Neurology 87 (19), 1985-1992, 2016 | 66 | 2016 |
| Efficacy and safety of alemtuzumab through 9 years of follow-up in patients with highly active disease: post hoc analysis of CARE-MS I and II patients in the TOPAZ extension study T Ziemssen, AD Bass, R Berkovich, G Comi, S Eichau, J Hobart, ... CNS drugs 34, 973-988, 2020 | 46 | 2020 |
| Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223 B Steingo, Y Al Malik, AD Bass, R Berkovich, M Carraro, Ó Fernández, ... Journal of Neurology 267, 3343-3353, 2020 | 42 | 2020 |
| Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial AJ Coles, DL Arnold, AD Bass, AL Boster, DAS Compston, Ó Fernández, ... Therapeutic Advances in Neurological Disorders 14, 1756286420982134, 2021 | 40 | 2021 |
| Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MS DL Arnold, E Fisher, VV Brinar, JA Cohen, AJ Coles, G Giovannoni, ... Neurology 87 (14), 1464-1472, 2016 | 30 | 2016 |
| Pregnancy outcomes and postpartum relapse rates in women with RRMS treated with alemtuzumab in the phase 2 and 3 clinical development program over 16 years J Oh, A Achiron, EG Celius, C Chambers, J Derwenskus, V Devonshire, ... Multiple Sclerosis and Related Disorders 43, 102146, 2020 | 25 | 2020 |
| Alemtuzumab improves neurological functional systems in treatment-naive relapsing-remitting multiple sclerosis patients EJ Fox, D Wynn, AJ Coles, J Palmer, DH Margolin, ... Journal of the Neurological Sciences 363, 188-194, 2016 | 24 | 2016 |
| Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: pooled analysis of the CARE-MS, extension, and TOPAZ … G Comi, R Alroughani, AL Boster, AD Bass, R Berkovich, Ó Fernández, ... Multiple Sclerosis Journal 26 (14), 1866-1876, 2020 | 22 | 2020 |
| Лекции по общей физиотерапии ВВ Оржешковский, ВВ Оржешковский К.: Купрыднова 1, 300-302, 2005 | 21 | 2005 |
| Ceruloplasmin: Its role in the physiological and pathological processes VV Orzheshkovskyi, MA Trishchynska Neurophysiology 51, 141-149, 2019 | 17 | 2019 |
| Proportion of alemtuzumab-treated patients converting from relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis over 6 years D Horáková, A Boster, A Bertolotto, MS Freedman, I Firmino*, SJ Cavalier, ... Multiple Sclerosis Journal–Experimental, Translational and Clinical 6 (4 …, 2020 | 14 | 2020 |
| Оржешковский Вас ВВ Оржешковский, ИЗ Самосюк В. Энциклопедический словарь терминов, употребляемых в физиотерапии …, 2004 | 14* | 2004 |
| Alemtuzumab outcomes by age: Post hoc analysis from the randomized CARE-MS studies over 8 years AD Bass, R Arroyo, AL Boster, AN Boyko, S Eichau, C Ionete, V Limmroth, ... Multiple Sclerosis and Related Disorders 49, 102717, 2021 | 12 | 2021 |
| Сучасні аспекти фармакотерапії порушень згортальної та протизгортальної систем при ішемічному інсульті ВВ Оржешковський, НМ Невмержицька Ліки України, 47-51, 2009 | 12 | 2009 |
| Бишофитотерапия ВВО В. В. Оржешковский Вестн. физиотерапии и курортологии, 62-71, 2005 | 12* | 2005 |
| Efficacy and safety of alemtuzumab in patients of african descent with relapsing-remitting multiple sclerosis: 8-year follow-up of CARE-MS I and II (TOPAZ study) AF Okai, L Amezcua, RR Berkovich, AR Chinea, KR Edwards, B Steingo, ... Neurology and Therapy 8, 367-381, 2019 | 9 | 2019 |
| Сучасні аспекти діагностики та лікування полінейропатії В Оржешковський, В Малий Ліки України 11, 88, 2004 | 8 | 2004 |
Alasdair ColesUniversity of CambridgeVerified email at medschl.cam.ac.uk
